Shire Prepares To Compete With Genzyme In Gaucher Market With 15% Price Discount
This article was originally published in The Pink Sheet Daily
Executive Summary
During its 2009 earnings call, the company also reported significant sales increase for its Replagal drug for Fabry disease.